Pricing Log in Create free account
Friday 6 November 2026 Export DNTH’s income statement to Excel — free account

Dianthus Therapeutics, Inc.

DNTH Healthcare Biotechnology

Dianthus Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 million, down 67.3% from fiscal 2024.

Revenue
+205.6%
EPS
+16.1%
Free cash flow
−65.9%

Quarter to September 2026, against a year earlier

86.43 3.42 +4.12%
Market cap
$4.6B
P/E
0.0×
Fwd P/E
−21.5×
Dividend yield
—
F-score
2/9
Altman Z
24.31
Beneish M
−4.75
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Dianthus Therapeutics, Inc. (DNTH) Revenue

Alert me on Revenue

Dianthus Therapeutics, Inc.'s revenue for fiscal 2025 was $2.0M, down 67.3% from $6.2M in fiscal 2024. Over the twelve months to 30 September 2026 it was $2.7M. Dianthus Therapeutics, Inc. ranks 273rd of 390 Biotechnology companies by revenue.

Revenue, annual

Embed this chart

Annual newest first

Period Revenue Change
FY2025 $2.0M (67.35%)
FY2024 $6.2M 120.63%
FY2023 $2.8M (55.96%)
FY2022 $6.4M —

Quarterly newest first

Period Revenue Change
Sep 2026 $1.2M 59.00%
Jun 2026 $761.0K 64.36%
Mar 2026 $463.0K 63.03%
Dec 2025 $284.0K (28.28%)
13 more quarters

Revenue against peers

Company Revenue
LEGN Legend Biotech Corporation Sponsored ADR compare $1.3B
TVTX Travere Therapeutics, Inc. compare $651.0M
CRSP CRISPR Therapeutics AG compare $25.2M
COGT Cogent Biosciences, Inc. compare $23.2M
DNTH Dianthus Therapeutics, Inc. $2.7M
EWTX Edgewise Therapeutics, Inc. compare —
DFTX Definium Therapeutics, Inc. compare —
ERAS Erasca, Inc. compare —
MANE Veradermics Incorporated compare —

What Revenue is

Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.

Reported line item

The full definition of Revenue →

More on DNTH